|
US7013219B2
(en)
*
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US7030215B2
(en)
*
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US20020164575A1
(en)
*
|
1999-09-14 |
2002-11-07 |
Sangamo Biosciences, Inc., A Delaware Corporation |
Gene identification
|
|
AU776576B2
(en)
*
|
1999-12-06 |
2004-09-16 |
Sangamo Biosciences, Inc. |
Methods of using randomized libraries of zinc finger proteins for the identification of gene function
|
|
US20020061512A1
(en)
*
|
2000-02-18 |
2002-05-23 |
Kim Jin-Soo |
Zinc finger domains and methods of identifying same
|
|
US20020055112A1
(en)
*
|
2000-08-26 |
2002-05-09 |
Nila Patil |
Methods for reducing complexity of nucleic acid samples
|
|
US20020164634A1
(en)
*
|
2000-08-26 |
2002-11-07 |
Perlegen Sciences, Inc. |
Methods for reducing complexity of nucleic acid samples
|
|
AU2002249170B2
(en)
*
|
2001-02-02 |
2007-02-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V |
Method for identifying functional nucleic acids
|
|
CA2457095A1
(en)
*
|
2001-08-17 |
2003-02-27 |
Toolgen, Inc. |
Zinc finger domain libraries
|
|
CN100463962C
(zh)
*
|
2001-12-07 |
2009-02-25 |
图尔金株式会社 |
嵌合蛋白质的表型筛选
|
|
US20040259258A1
(en)
*
|
2001-12-07 |
2004-12-23 |
Kim Jin-Soo |
Regulation of prokaryotic gene expression with zinc finger proteins
|
|
WO2003087341A2
(en)
|
2002-01-23 |
2003-10-23 |
The University Of Utah Research Foundation |
Targeted chromosomal mutagenesis using zinc finger nucleases
|
|
US20060078880A1
(en)
*
|
2002-02-07 |
2006-04-13 |
The Scripps Research Institute |
Zinc finger libraries
|
|
US20030180777A1
(en)
*
|
2002-03-12 |
2003-09-25 |
Victor Bartsevich |
Rapid identification of transcriptional regulatory domains
|
|
AU2003260973A1
(en)
*
|
2002-09-05 |
2004-03-29 |
Toolgen, Inc. |
Bioinformatics analysis of cellular effects of artificial transcription factors
|
|
EP2806025B1
(de)
|
2002-09-05 |
2019-04-03 |
California Institute of Technology |
Verwendung von Zinkfingernukleasen zur Stimulierung von Gentargeting
|
|
US20050069896A1
(en)
*
|
2002-09-12 |
2005-03-31 |
Horvitz H. Robert |
Rb pathway and chromatin remodeling genes that antagonize let-60 Ras signaling
|
|
US20070178454A1
(en)
*
|
2002-10-21 |
2007-08-02 |
Joung J K |
Context sensitive paralell optimization of zinc finger dna binding domains
|
|
AU2003304087A1
(en)
*
|
2002-10-23 |
2004-11-26 |
The General Hospital Corporation |
Methods for producing zinc finger proteins that bind to extended dna target sequences
|
|
AU2003295692A1
(en)
*
|
2002-11-15 |
2004-06-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for analysis of regulatory sequences
|
|
US20060251643A1
(en)
*
|
2002-12-09 |
2006-11-09 |
Toolgen, Inc. |
Regulatory zinc finger proteins
|
|
US20060183132A1
(en)
*
|
2005-02-14 |
2006-08-17 |
Perlegen Sciences, Inc. |
Selection probe amplification
|
|
US20090124514A1
(en)
*
|
2003-02-26 |
2009-05-14 |
Perlegen Sciences, Inc. |
Selection probe amplification
|
|
US20050100911A1
(en)
*
|
2003-08-06 |
2005-05-12 |
Perlegen Sciences, Inc. |
Methods for enriching populations of nucleic acid samples
|
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
AU2005287278B2
(en)
*
|
2004-09-16 |
2011-08-04 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
|
BRPI0612287A8
(pt)
|
2005-06-27 |
2019-01-22 |
Exelixis Inc |
composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
|
|
US7718131B2
(en)
*
|
2005-07-06 |
2010-05-18 |
Genetix Limited |
Methods and apparatus for imaging and processing of samples in biological sample containers
|
|
US20070148674A1
(en)
*
|
2005-12-23 |
2007-06-28 |
Wisconsin Alumni Research Foundation (Warf) |
Optical fingerprinting of nucleic acid sequences
|
|
US20070178499A1
(en)
*
|
2006-01-06 |
2007-08-02 |
The Scripps Research Institute |
Specific Labeling of Protein with Zinc Finger Tags and Use of Zinc-Finger-Tagged Proteins for Analysis
|
|
KR100756055B1
(ko)
*
|
2006-01-27 |
2007-09-07 |
연세대학교 산학협력단 |
신생혈관 생성을 조절하는 재조합 아데노바이러스
|
|
US7763441B2
(en)
|
2006-03-13 |
2010-07-27 |
Wyeth |
Modulators of gluconeogenesis
|
|
WO2007136685A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivation of dihydrofolate reductase
|
|
EP2027262B1
(de)
|
2006-05-25 |
2010-03-31 |
Sangamo Biosciences Inc. |
Variante foki-spaltungshälften-domänen
|
|
ES2465996T3
(es)
|
2006-05-25 |
2014-06-09 |
Sangamo Biosciences, Inc. |
Métodos y composiciones para la inactivación genética
|
|
BRPI0716427A2
(pt)
|
2006-08-11 |
2014-03-11 |
Dow Agrosciences Llc |
Recombinação homóloga mediada por nuclease de apêndice de zinco
|
|
WO2008060510A2
(en)
|
2006-11-13 |
2008-05-22 |
Sangamo Biosciences, Inc. |
Zinc finger nuclease for targeting the human glucocorticoid receptor locus
|
|
EP2171052B1
(de)
|
2007-07-12 |
2014-08-27 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzung zur deaktivierung der alpha-1,6-fucosyltransferase-genexpression
|
|
AU2008305590A1
(en)
*
|
2007-09-27 |
2009-04-02 |
Sangamo Therapeutics, Inc. |
Genomic editing in zebrafish using zinc finger nucleases
|
|
HRP20161004T1
(hr)
*
|
2007-09-27 |
2016-10-21 |
Dow Agrosciences Llc |
Tehnološki konstruirani proteini cinkovi prsti koji imaju kao cilj gene za sintazu 5-enolpiruvilshikimat-3-fosfata
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
EP2205752B1
(de)
|
2007-10-25 |
2016-08-10 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen für gezielte integration
|
|
WO2009146179A1
(en)
*
|
2008-04-15 |
2009-12-03 |
University Of Iowa Research Foundation |
Zinc finger nuclease for the cftr gene and methods of use thereof
|
|
WO2009151591A2
(en)
|
2008-06-10 |
2009-12-17 |
Sangamo Biosciences, Inc. |
Methods and compositions for generation of bax- and bak-deficient cell lines
|
|
SG191561A1
(en)
|
2008-08-22 |
2013-07-31 |
Sangamo Biosciences Inc |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
|
JP5756016B2
(ja)
|
2008-10-29 |
2015-07-29 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
グルタミンシンセターゼ遺伝子の発現を不活性化する方法及び組成物
|
|
EP2352369B1
(de)
|
2008-12-04 |
2017-04-26 |
Sangamo BioSciences, Inc. |
Genomänderung bei ratten mithilfe von zink-finger-nukleasen
|
|
AU2010211057B2
(en)
|
2009-02-04 |
2014-12-18 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating neuropathies
|
|
EP2408921B1
(de)
|
2009-03-20 |
2017-04-19 |
Sangamo BioSciences, Inc. |
Modifikation von cxcr4 mit manipulierten zink-fingerproteinen
|
|
EP2419511B1
(de)
|
2009-04-09 |
2018-01-17 |
Sangamo Therapeutics, Inc. |
Gezielte integration in stammzellen
|
|
CA2769262C
(en)
|
2009-07-28 |
2019-04-30 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating trinucleotide repeat disorders
|
|
US8586526B2
(en)
|
2010-05-17 |
2013-11-19 |
Sangamo Biosciences, Inc. |
DNA-binding proteins and uses thereof
|
|
US8956828B2
(en)
*
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
MX336846B
(es)
*
|
2010-01-22 |
2016-02-03 |
Sangamo Biosciences Inc |
Alteracion genomica dirigida.
|
|
ES2751916T3
(es)
|
2010-02-08 |
2020-04-02 |
Sangamo Therapeutics Inc |
Semidominios de escisión genomanipulados
|
|
EP2660318A1
(de)
|
2010-02-09 |
2013-11-06 |
Sangamo BioSciences, Inc. |
Gezielte Genommodifikation mit partiell einzelsträngigen Donatormolekülen
|
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
|
AU2011281062B2
(en)
|
2010-07-21 |
2015-01-22 |
Board Of Regents, The University Of Texas System |
Methods and compositions for modification of a HLA locus
|
|
AU2011312562B2
(en)
|
2010-09-27 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
|
US9175280B2
(en)
|
2010-10-12 |
2015-11-03 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating hemophilia B
|
|
WO2012094132A1
(en)
|
2011-01-05 |
2012-07-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
|
JP6214530B2
(ja)
|
2011-07-15 |
2017-10-18 |
ザ ジェネラル ホスピタル コーポレイション |
転写活性化因子様エフェクターの組立て方法
|
|
US10323236B2
(en)
|
2011-07-22 |
2019-06-18 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
US9161995B2
(en)
|
2011-07-25 |
2015-10-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
|
CA2848417C
(en)
|
2011-09-21 |
2023-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of transgene expression
|
|
CA3099582A1
(en)
|
2011-10-27 |
2013-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the hprt locus
|
|
HK1200871A1
(en)
|
2011-11-16 |
2015-08-14 |
Sangamo Therapeutics, Inc. |
Modified dna-binding proteins and uses thereof
|
|
WO2013130824A1
(en)
|
2012-02-29 |
2013-09-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
|
SG11201406547YA
(en)
*
|
2012-04-25 |
2014-11-27 |
Regeneron Pharma |
Nuclease-mediated targeting with large targeting vectors
|
|
MX369788B
(es)
*
|
2012-05-02 |
2019-11-21 |
Dow Agrosciences Llc |
Modificacion dirigida de deshidrogenasa de malato.
|
|
AU2013259647B2
(en)
|
2012-05-07 |
2018-11-08 |
Corteva Agriscience Llc |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
EP3196301B1
(de)
|
2012-07-11 |
2018-10-17 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur behandlung von monogener krankheiten
|
|
JP6329537B2
(ja)
|
2012-07-11 |
2018-05-23 |
サンガモ セラピューティクス, インコーポレイテッド |
生物学的薬剤の送達のための方法および組成物
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
SG10201701601WA
(en)
|
2012-08-29 |
2017-04-27 |
Sangamo Biosciences Inc |
Methods and compositions for treatment of a genetic condition
|
|
KR102357105B1
(ko)
|
2012-09-04 |
2022-02-08 |
더 스크립스 리서치 인스티튜트 |
표적화된 바인딩 특이도를 갖는 키메라 폴리펩타이드들
|
|
US9914930B2
(en)
|
2012-09-07 |
2018-03-13 |
Dow Agrosciences Llc |
FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
|
UA119135C2
(uk)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб отримання трансгенної рослини
|
|
AU2013329186B2
(en)
|
2012-10-10 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
EP3789405A1
(de)
|
2012-10-12 |
2021-03-10 |
The General Hospital Corporation |
Transkriptionsaktivator-like-effektor-lysinspezifische demethylase-1 (lsd1)-fusionsproteine
|
|
US9255250B2
(en)
|
2012-12-05 |
2016-02-09 |
Sangamo Bioscience, Inc. |
Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
|
|
EP2928303A4
(de)
|
2012-12-07 |
2016-07-13 |
Haplomics Inc |
Faktor-viii-mutationsreparatur und toleranzinduktion
|
|
EP2954042B1
(de)
|
2013-02-07 |
2017-12-06 |
The General Hospital Corporation |
Tale-transkriptionsaktivatoren
|
|
US10227610B2
(en)
|
2013-02-25 |
2019-03-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
US11332719B2
(en)
*
|
2013-03-15 |
2022-05-17 |
The Broad Institute, Inc. |
Recombinant virus and preparations thereof
|
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
|
CN112301024A
(zh)
|
2013-03-15 |
2021-02-02 |
通用医疗公司 |
使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
US9937207B2
(en)
|
2013-03-21 |
2018-04-10 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell receptor genes using talens
|
|
DK3456831T3
(da)
|
2013-04-16 |
2021-09-06 |
Regeneron Pharma |
Målrettet modifikation af rottegenom
|
|
EP2994531B1
(de)
|
2013-05-10 |
2018-03-28 |
Sangamo Therapeutics, Inc. |
Freisetzungsverfahren und zusammensetzungen für nukleasevermitteltes genomengineering
|
|
CN105683376A
(zh)
|
2013-05-15 |
2016-06-15 |
桑格摩生物科学股份有限公司 |
用于治疗遗传病状的方法和组合物
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
CA3131284C
(en)
|
2013-08-28 |
2023-09-19 |
David Paschon |
Compositions for linking dna-binding domains and cleavage domains
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
|
EP3441468B1
(de)
|
2013-10-17 |
2021-05-19 |
Sangamo Therapeutics, Inc. |
Freisetzungsverfahren und zusammensetzungen für nukleasevermitteltes genomengineering
|
|
US10117899B2
(en)
|
2013-10-17 |
2018-11-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
UY35812A
(es)
|
2013-11-04 |
2015-05-29 |
Dow Agrosciences Llc |
?loci de maíz óptimos?.
|
|
NZ719494A
(en)
|
2013-11-04 |
2017-09-29 |
Dow Agrosciences Llc |
Optimal maize loci
|
|
NZ746567A
(en)
|
2013-11-04 |
2019-09-27 |
Dow Agrosciences Llc |
Optimal soybean loci
|
|
CN106459995B
(zh)
|
2013-11-07 |
2020-02-21 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
WO2015070212A1
(en)
|
2013-11-11 |
2015-05-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
|
DK3492593T3
(da)
|
2013-11-13 |
2021-11-08 |
Childrens Medical Center |
Nukleasemedieret regulering af genekspression
|
|
CN105940013B
(zh)
|
2013-12-09 |
2020-03-27 |
桑格摩生物科学股份有限公司 |
用于治疗血友病的方法和组合物
|
|
KR102170502B1
(ko)
|
2013-12-11 |
2020-10-28 |
리제너론 파마슈티칼스 인코포레이티드 |
게놈의 표적화된 변형을 위한 방법 및 조성물
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
US10072066B2
(en)
|
2014-02-03 |
2018-09-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a beta thalessemia
|
|
WO2015127439A1
(en)
|
2014-02-24 |
2015-08-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
CN106459894B
(zh)
|
2014-03-18 |
2020-02-18 |
桑格摩生物科学股份有限公司 |
用于调控锌指蛋白表达的方法和组合物
|
|
WO2015164748A1
(en)
|
2014-04-24 |
2015-10-29 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (tale) proteins
|
|
WO2015171932A1
(en)
|
2014-05-08 |
2015-11-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
|
WO2015175642A2
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
|
WO2015188056A1
(en)
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
|
HRP20200529T1
(hr)
|
2014-06-06 |
2020-09-04 |
Regeneron Pharmaceuticals, Inc. |
Postupci i pripravci za modificiranje ciljnog lokusa
|
|
CN106604994B
(zh)
|
2014-06-23 |
2021-12-14 |
通用医疗公司 |
通过测序评估的DSBs的全基因组无偏鉴定(GUIDE-Seq)
|
|
SI3161128T1
(sl)
|
2014-06-26 |
2019-02-28 |
Regeneron Pharmaceuticals, Inc. |
Postopki in sestavki za ciljano genetsko spremembo in postopki uporabe
|
|
DK3169778T5
(da)
|
2014-07-14 |
2024-10-14 |
Univ Washington State |
Nanos-knockout, der eliminerer kimbaneceller
|
|
KR20170032406A
(ko)
|
2014-07-15 |
2017-03-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료를 위한 조작된 세포
|
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
DK3194570T3
(da)
|
2014-09-16 |
2021-09-13 |
Sangamo Therapeutics Inc |
Fremgangsmåder og sammensætninger til nukleasemedieret genommodificering og -korrektion i hæmatopoietiske stamceller
|
|
EP3201340B1
(de)
|
2014-10-01 |
2020-12-02 |
The General Hospital Corporation |
Verfahren zur erhöhung der effizienz von nucleaseinduzierter homologiegerichteter reparatur
|
|
KR102531016B1
(ko)
|
2014-11-21 |
2023-05-10 |
리제너론 파마슈티칼스 인코포레이티드 |
쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
ES2947714T3
(es)
|
2014-12-19 |
2023-08-17 |
Regeneron Pharma |
Métodos y composiciones para la modificación genética dirigida a través de múltiples direccionamientos en un solo paso
|
|
HK1246690A1
(zh)
|
2015-01-21 |
2018-09-14 |
Sangamo Therapeutics, Inc. |
用於鉴定高度特异性核酸酶的方法和组合物
|
|
CA2981077A1
(en)
|
2015-04-03 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
AU2016261927B2
(en)
|
2015-05-12 |
2022-04-07 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
EP3302525A2
(de)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
AU2016291778B2
(en)
|
2015-07-13 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
HK1255161A1
(zh)
|
2015-07-15 |
2019-08-09 |
Juno Therapeutics, Inc. |
用於过继性细胞治疗的工程细胞
|
|
RS65691B1
(sr)
|
2015-08-06 |
2024-07-31 |
Univ Missouri |
Svinja i ćelije rezistentne na virus reproduktivnog i respiratornog sindroma svinja (prrsv) koje imaju modifikovane cd163 gene
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
WO2017044843A1
(en)
|
2015-09-11 |
2017-03-16 |
The General Hospital Corporation |
Full interrogation of nuclease dsbs and sequencing (find-seq)
|
|
JP6853257B2
(ja)
|
2015-09-23 |
2021-03-31 |
サンガモ セラピューティクス, インコーポレイテッド |
Httリプレッサー及びその使用
|
|
JP2018529353A
(ja)
|
2015-09-30 |
2018-10-11 |
ザ ジェネラル ホスピタル コーポレイション |
配列決定法による切断事象の包括的生体外報告(CIRCLE−seq)
|
|
IL310721B2
(en)
|
2015-10-23 |
2025-11-01 |
Harvard College |
Nucleobase editors and uses thereof
|
|
MY189674A
(en)
|
2015-10-28 |
2022-02-24 |
Sangamo Therapeutics Inc |
Liver-specific constructs, factor viii expression cassettes and methods of use thereof
|
|
US10639383B2
(en)
|
2015-11-23 |
2020-05-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
|
EP3389677B1
(de)
|
2015-12-18 |
2024-06-26 |
Sangamo Therapeutics, Inc. |
Gezielte zerstörung des t-zell-rezeptors
|
|
BR112018012235A2
(pt)
|
2015-12-18 |
2018-12-04 |
Sangamo Therapeutics Inc |
rompimento alvejado do receptor de células de mhc
|
|
WO2017123757A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
KR20180101442A
(ko)
|
2016-02-02 |
2018-09-12 |
상가모 테라퓨틱스, 인코포레이티드 |
Dna-결합 도메인 및 절단 도메인을 연결시키기 위한 조성물
|
|
CA3025523A1
(en)
|
2016-05-27 |
2017-11-30 |
Aadigen, Llc |
Peptides and nanoparticles for intracellular delivery of genome-editing molecules
|
|
MA45670A
(fr)
|
2016-07-13 |
2019-05-22 |
Vertex Pharma |
Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome
|
|
CN110214183A
(zh)
|
2016-08-03 |
2019-09-06 |
哈佛大学的校长及成员们 |
腺苷核碱基编辑器及其用途
|
|
WO2018031683A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
EP3995574A1
(de)
|
2016-08-24 |
2022-05-11 |
Sangamo Therapeutics, Inc. |
Regulierung der genexpression mit manipulierten nukleasen
|
|
KR102455249B1
(ko)
|
2016-08-24 |
2022-10-17 |
상가모 테라퓨틱스, 인코포레이티드 |
가공된 표적 특이적 뉴클레아제
|
|
CA3035534A1
(en)
|
2016-09-07 |
2018-03-15 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
JP7248571B2
(ja)
|
2016-10-05 |
2023-03-29 |
フジフィルム セルラー ダイナミクス,インコーポレイテッド |
MeCP2が破壊された誘導多能性幹細胞からの成熟系列の生成
|
|
JP7623784B2
(ja)
|
2016-10-13 |
2025-01-29 |
ジュノー セラピューティクス インコーポレイテッド |
トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
|
|
KR20190067209A
(ko)
|
2016-10-14 |
2019-06-14 |
더 제너럴 하스피탈 코포레이션 |
후성적으로 조절되는 부위-특이적 뉴클레아제
|
|
KR102622411B1
(ko)
|
2016-10-14 |
2024-01-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
KR102712926B1
(ko)
|
2016-10-20 |
2024-10-07 |
상가모 테라퓨틱스, 인코포레이티드 |
파브리병의 치료를 위한 방법 및 조성물
|
|
WO2018081775A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
IL266862B2
(en)
|
2016-12-01 |
2024-01-01 |
Sangamo Therapeutics Inc |
Tau modulators and methods and preparations for their administration
|
|
US11793833B2
(en)
|
2016-12-02 |
2023-10-24 |
Juno Therapeutics, Inc. |
Engineered B cells and related compositions and methods
|
|
EP3551754B1
(de)
|
2016-12-08 |
2023-08-30 |
Case Western Reserve University |
Verfahren und zusammensetzungen zur erhöhung der herstellung von funktionalem myelin
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
EP3592853A1
(de)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Unterdrückung von schmerzen durch geneditierung
|
|
US12390514B2
(en)
|
2017-03-09 |
2025-08-19 |
President And Fellows Of Harvard College |
Cancer vaccine
|
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
|
KR20240116572A
(ko)
|
2017-03-23 |
2024-07-29 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
|
MX2019011772A
(es)
|
2017-04-03 |
2020-01-09 |
Encoded Therapeutics Inc |
Expresion transgenica selectiva de tejidos.
|
|
LT3615674T
(lt)
|
2017-04-28 |
2024-09-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Reumatoidinio artrito gydymo būdai, naudojant nukreipiančios rnr hla geno redagavimą genome
|
|
CN110799492B
(zh)
|
2017-04-28 |
2023-06-27 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
|
US11655275B2
(en)
|
2017-05-03 |
2023-05-23 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
EP3630849A4
(de)
|
2017-05-25 |
2021-01-13 |
The General Hospital Corporation |
Architekturen von zweiteiligem basiseditor (bbe) und typ-ii-c-cas9-zinkfinger-editing
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
CN111164211B
(zh)
|
2017-07-18 |
2024-08-02 |
杰特贝林基因治疗股份有限公司 |
用于治疗β-血红蛋白病的组合物和方法
|
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
|
AU2018313167A1
(en)
|
2017-08-08 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Chimeric antigen receptor mediated cell targeting
|
|
EP3676376B1
(de)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
Hocheffiziente baseneditoren mit gam
|
|
KR20250107288A
(ko)
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
BR112020008568A2
(pt)
|
2017-11-09 |
2020-10-06 |
Sangamo Therapeutics, Inc. |
modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish)
|
|
EP3717505A4
(de)
|
2017-12-01 |
2021-12-01 |
Encoded Therapeutics, Inc. |
Gentechnisch veränderte dna-bindende proteine
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
MA51619A
(fr)
|
2018-01-17 |
2021-04-14 |
Vertex Pharma |
Inhibiteurs de la protéine kinase dépendante de l'adn
|
|
JP7466448B2
(ja)
|
2018-01-17 |
2024-04-12 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Dna-pk阻害剤
|
|
BR112020013626A2
(pt)
|
2018-01-17 |
2020-12-01 |
Vertex Pharmaceuticals Incorporated |
compostos de quinoxalinona, composições, métodos e kits para aumentar a eficiência de edição de genoma
|
|
CA3089587A1
(en)
|
2018-02-08 |
2019-08-15 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
|
MA52207A
(fr)
|
2018-04-05 |
2021-02-17 |
Editas Medicine Inc |
Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés
|
|
CA3094468A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
|
US11421007B2
(en)
|
2018-04-18 |
2022-08-23 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (Htt)
|
|
KR20250133482A
(ko)
|
2018-05-11 |
2025-09-05 |
빔 테라퓨틱스, 인크. |
프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
CA3108281A1
(en)
|
2018-08-03 |
2020-02-06 |
Beam Therapeutics Inc. |
Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence
|
|
AU2019326408A1
(en)
|
2018-08-23 |
2021-03-11 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
|
WO2020051283A1
(en)
|
2018-09-05 |
2020-03-12 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
|
KR20210060533A
(ko)
|
2018-09-18 |
2021-05-26 |
상가모 테라퓨틱스, 인코포레이티드 |
프로그램화된 세포 사멸 1 (pd1) 특이적 뉴클레아제
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
WO2020072677A1
(en)
|
2018-10-02 |
2020-04-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulation of tau proteins
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
US20220282275A1
(en)
|
2018-11-15 |
2022-09-08 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
|
EP3886869A4
(de)
|
2018-11-28 |
2022-07-06 |
Forty Seven, Inc. |
Genetisch modifizierte ablationsresistente hspcs
|
|
US12390812B2
(en)
|
2018-12-19 |
2025-08-19 |
Nuclein, Llc |
Apparatus and methods for molecular diagnostics
|
|
EP3908291A4
(de)
|
2019-01-07 |
2023-01-11 |
Dana-Farber Cancer Institute, Inc. |
Niedermolekulare degrader von fkbp12 über rekrutierung der von-hippel-lindau-e3-ubiquitin-ligase (vhl) und verwendung in dtag-systemen
|
|
PT3908568T
(pt)
|
2019-01-11 |
2024-09-30 |
Acuitas Therapeutics Inc |
Lípidos para a administração de agentes ativos por nanopartículas lipídicas
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
|
US11866469B2
(en)
|
2019-02-06 |
2024-01-09 |
Klogenix Llc |
DNA binding proteins and uses thereof
|
|
AU2019428629A1
(en)
|
2019-02-06 |
2021-01-28 |
Sangamo Therapeutics, Inc. |
Method for the treatment of mucopolysaccharidosis type I
|
|
WO2020181193A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
|
WO2020191233A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
CA3132167A1
(en)
|
2019-04-02 |
2020-10-08 |
Weston P. MILLER IV |
Methods for the treatment of beta-thalassemia
|
|
CA3136119A1
(en)
|
2019-04-10 |
2020-10-15 |
University Of Utah Research Foundation |
Htra1 modulation for treatment of amd
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
TW202521561A
(zh)
|
2019-04-23 |
2025-06-01 |
美商聖加莫治療股份有限公司 |
染色體9開放讀框72基因表現之調節子及其用途
|
|
CA3136742A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
WO2020223535A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
PL3976798T3
(pl)
|
2019-05-29 |
2026-04-07 |
Encoded Therapeutics, Inc. |
Kompozycje i sposoby selektywnej regulacji genów
|
|
WO2021022043A2
(en)
|
2019-07-30 |
2021-02-04 |
Pairwise Plants Services, Inc. |
Morphogenic regulators and methods of using the same
|
|
US20220267732A1
(en)
|
2019-08-01 |
2022-08-25 |
Sana Biotechnology, Inc. |
Dux4 expressing cells and uses thereof
|
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
|
JP7728747B2
(ja)
|
2019-08-23 |
2025-08-25 |
サナ バイオテクノロジー,インコーポレイテッド |
Cd24発現細胞およびそれらの用途
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
DK3812472T3
(da)
|
2019-10-21 |
2023-02-20 |
Univ Freiburg Albert Ludwigs |
Virkelig uvildig in vitro-undersøgelse til profilering af off-target-aktivitet af en eller flere målspecifikke programmerbare nukleaser i celler (abnoba-seq)
|
|
US20210130828A1
(en)
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Gin recombinase variants
|
|
WO2021087361A1
(en)
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Zinc finger nuclease variants for treating or preventing lysosomal storage diseases
|
|
US20230086199A1
(en)
|
2019-11-26 |
2023-03-23 |
The Broad Institute, Inc. |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
|
EP4100519A2
(de)
|
2020-02-05 |
2022-12-14 |
The Broad Institute, Inc. |
Adeninbaseneditoren und verwendungen davon
|
|
CN116209756A
(zh)
|
2020-03-04 |
2023-06-02 |
旗舰先锋创新Vi有限责任公司 |
调控基因组的方法和组合物
|
|
EP4114951A4
(de)
|
2020-03-05 |
2024-05-08 |
The Regents Of The University Of California |
Verfahren zur herstellung von pflanzen mit minimiertem biomassenebenprodukt und zugehörige pflanzen davon
|
|
KR20220158046A
(ko)
|
2020-03-25 |
2022-11-29 |
사나 바이오테크놀로지, 인크. |
신경계 장애 및 병태의 치료를 위한 면역저하성 신경 세포
|
|
US11091524B1
(en)
|
2020-04-22 |
2021-08-17 |
Houston Gene Therapeutics Llc |
Compositions for treatment of vascular disease
|
|
EP4143315A1
(de)
|
2020-04-28 |
2023-03-08 |
The Broad Institute Inc. |
<smallcaps/>?ush2a? ?gezielte basisbearbeitung eines thegens
|
|
EP4146284A1
(de)
|
2020-05-06 |
2023-03-15 |
Cellectis S.A. |
Verfahren zur genetischen modifizierung von zellen zur freisetzung therapeutischer proteine
|
|
CN115803435A
(zh)
|
2020-05-06 |
2023-03-14 |
塞勒克提斯公司 |
用于在细胞基因组中靶向插入外源序列的方法
|
|
CN111549061A
(zh)
*
|
2020-05-07 |
2020-08-18 |
西南大学 |
一种高通量筛选真核生物细胞响应环境极端pH的靶点基因的方法
|
|
IL297761A
(en)
|
2020-05-08 |
2022-12-01 |
Broad Inst Inc |
Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
|
|
CN115835873A
(zh)
|
2020-05-13 |
2023-03-21 |
朱诺治疗学股份有限公司 |
用于产生表达重组受体的供体分批细胞的方法
|
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
JP2023531531A
(ja)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
組換え受容体を条件付きで発現する操作されたt細胞、関連ポリヌクレオチド、および方法
|
|
ES3054438T3
(en)
|
2020-07-16 |
2026-02-03 |
Acuitas Therapeutics Inc |
Cationic lipids for use in lipid nanoparticles
|
|
WO2022036150A1
(en)
|
2020-08-13 |
2022-02-17 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
|
US12152251B2
(en)
|
2020-08-25 |
2024-11-26 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
EP4240756A1
(de)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Zellen zur expression eines chimären rezeptors aus einem modifizierten invarianten kettenlocus der cd3-immunglobulin-superfamilie und zugehörige polynukleotide und verfahren
|
|
US20240000051A1
(en)
|
2020-11-16 |
2024-01-04 |
Pig Improvement Company Uk Limited |
Influenza a-resistant animals having edited anp32 genes
|
|
JP2024501971A
(ja)
|
2020-12-31 |
2024-01-17 |
サナ バイオテクノロジー,インコーポレイテッド |
Car-t活性を調節するための方法及び組成物
|
|
EP4277933A4
(de)
|
2021-01-14 |
2024-12-11 |
Senti Biosciences, Inc. |
Sekretierbare nutzlastregulierung
|
|
CA3208612A1
(en)
|
2021-02-19 |
2022-08-25 |
Beam Therapeutics Inc. |
Recombinant rabies viruses for gene therapy
|
|
CA3213080A1
(en)
|
2021-03-23 |
2022-09-29 |
Krit RITTHIPICHAI |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
EP4341392A4
(de)
|
2021-05-14 |
2025-02-19 |
Becton Dickinson and Company |
Multiplexiertes unvorgespanntes nukleinsäureamplifikationsverfahren
|
|
AU2022272723A1
(en)
|
2021-05-14 |
2023-11-30 |
Becton, Dickinson And Company |
Methods for making libraries for nucleic acid sequencing
|
|
US20240226164A1
(en)
|
2021-05-27 |
2024-07-11 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
KR20240046319A
(ko)
|
2021-07-14 |
2024-04-08 |
사나 바이오테크놀로지, 인크. |
저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
|
|
AU2022327174A1
(en)
|
2021-08-11 |
2024-02-15 |
Sana Biotechnology, Inc. |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
US20240358761A1
(en)
|
2021-08-11 |
2024-10-31 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
EP4384598A1
(de)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetisch modifizierte zellen für allogene zelltherapie zur reduzierung komplementvermittelter entzündungsreaktionen
|
|
JP2024535677A
(ja)
|
2021-08-11 |
2024-10-02 |
サナ バイオテクノロジー,インコーポレイテッド |
即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
|
|
WO2023035011A1
(en)
|
2021-09-03 |
2023-03-09 |
North Carolina State University |
Compositions and methods for conferring resistance to geminivirus
|
|
CA3230629A1
(en)
|
2021-09-08 |
2023-03-16 |
Beam Therapeutics Inc. |
Viral guide rna delivery
|
|
AU2022343268A1
(en)
|
2021-09-08 |
2024-03-28 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating a genome
|
|
US20250313861A1
(en)
|
2021-10-22 |
2025-10-09 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
US20250064032A1
(en)
|
2021-12-10 |
2025-02-27 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
CN119072319A
(zh)
|
2021-12-23 |
2024-12-03 |
萨那生物技术股份有限公司 |
用于治疗自身免疫性疾病的嵌合抗原受体(car)t细胞及相关方法
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
US20250302953A1
(en)
|
2022-02-14 |
2025-10-02 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
EP4479416A1
(de)
|
2022-02-17 |
2024-12-25 |
Sana Biotechnology, Inc. |
Manipulierte cd47-proteine und verwendungen davon
|
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
US20250302994A1
(en)
|
2022-05-09 |
2025-10-02 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
|
EP4522201A1
(de)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvoviruszusammensetzungen und verfahren zur gentherapie
|
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
|
WO2024040083A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
WO2024155745A1
(en)
|
2023-01-18 |
2024-07-25 |
The Broad Institute, Inc. |
Base editing-mediated readthrough of premature termination codons (bert)
|
|
JP2026504491A
(ja)
|
2023-02-03 |
2026-02-05 |
ツェー3エス2 ゲーエムベーハー |
操作された免疫細胞の非ウイルス的製造のための方法
|
|
WO2024187174A2
(en)
|
2023-03-09 |
2024-09-12 |
Aadigen, Llc |
Compositions for treating cancer with kras mutations and uses thereof
|
|
US12383615B2
(en)
|
2023-03-23 |
2025-08-12 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
|
|
AU2024264889A1
(en)
|
2023-05-03 |
2025-11-13 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
EP4713027A1
(de)
|
2023-05-16 |
2026-03-25 |
Omega Therapeutics, Inc. |
Verfahren und zusammensetzungen zur modulation der methylierung eines zielgens
|
|
WO2024238723A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating pcsk9 expression
|
|
EP4716541A2
(de)
|
2023-05-22 |
2026-04-01 |
Sana Biotechnology, Inc. |
Verfahren zur abgabe von inselzellen und zugehörige verfahren
|
|
CN121729237A
(zh)
|
2023-06-30 |
2026-03-24 |
武田药品工业株式会社 |
Htt阻遏物及其用途
|
|
WO2025019742A1
(en)
|
2023-07-19 |
2025-01-23 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating ctnnb1 expression
|
|
AU2024335327A1
(en)
|
2023-09-01 |
2026-03-26 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025064469A1
(en)
|
2023-09-18 |
2025-03-27 |
Omega Therapeutics, Inc. |
Methods for assessing dosage for epigenetic modifying agents
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025193628A2
(en)
|
2024-03-09 |
2025-09-18 |
Aadigen, Llc |
Compositions for treating cancer with kras mutations and uses thereof
|
|
WO2025194124A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
Modified st1cas9 guide nucleic acids
|
|
WO2025235563A1
(en)
|
2024-05-07 |
2025-11-13 |
Omega Therapeutics, Inc. |
Epigenetic modulation for upregulation of genes
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
WO2026072421A2
(en)
|
2024-09-27 |
2026-04-02 |
The Broad Institute, Inc. |
Base editing methods and compositions for editing prnp in the treatment of prion disease
|
|
WO2026083329A1
(en)
|
2024-10-18 |
2026-04-23 |
Precision Biosciences, Inc. |
Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof
|
|
WO2026083328A1
(en)
|
2024-10-18 |
2026-04-23 |
Precision Biosciences, Inc. |
Base editing nucleotide sequences using homology directed repair
|